Curran Simpson
Known title: Chief Oper. & Tech. OfficerCIK: 0001346164
Associated companies
Transaction History
| RGNX | ▼ Sell | Tax Withholding | 6,818 | $89K | 7/1/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 1,453 | $15K | 6/30/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 144,864 | $0 | 1/6/2026 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 18,559 | $267K | 1/2/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 951 | $7K | 12/31/2025 | View on chart |
| RGNX | ▼ Sell | Open Market | 20,811 | $263K | 10/9/2025 | View on chart |
| RGNX | ▼ Sell | Open Market | 7,624 | $76K | 9/29/2025 | View on chart |
| RGNX | ▼ Sell | Open Market | 7,734 | $77K | 9/10/2025 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 4,701 | $39K | 7/1/2025 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 11,917 | $92K | 1/2/2025 | View on chart |
| RGNX | ▲ Buy | Grant | 98,912 | $0 | 1/2/2025 | View on chart |
| RGNX | ▼ Sell | Open Market | 100 | $2K | 8/1/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 9,648 | $145K | 7/29/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 56,458 | $0 | 7/1/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 38,462 | $0 | 1/2/2024 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 8,120 | $146K | 1/2/2024 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 2,076 | $47K | 1/3/2023 | View on chart |
| RGNX | ▲ Buy | Grant | 67,945 | $0 | 1/3/2023 | View on chart |
| RGNX | ▲ Buy | Grant | 10,700 | $0 | 1/3/2022 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 1,332 | $44K | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.